{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:02:15Z","timestamp":1781722935648,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":29,"publisher":"Springer US","isbn-type":[{"value":"9781071607701","type":"print"},{"value":"9781071607718","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0771-8_6","type":"book-chapter","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:02:49Z","timestamp":1598857369000},"page":"87-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis"],"prefix":"10.1007","author":[{"given":"Maria","family":"Mahfouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"2","key":"6_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini G, Merlini G (2016) What is new in diagnosis and management of light chain amyloidosis? Blood 128(2):159\u2013168. \nhttps:\/\/doi.org\/10.1182\/blood-2016-01-629790","journal-title":"Blood"},{"issue":"9","key":"6_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86(9):1036\u20131043. \nhttps:\/\/doi.org\/10.1136\/jnnp-2014-308724","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7 Suppl","key":"6_CR3","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA (2017) Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care 23(7 Suppl):S107\u2013S112","journal-title":"Am J Manag Care"},{"issue":"21","key":"6_CR4","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451\u20132466. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2015.09.075","journal-title":"J Am Coll Cardiol"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK (2019) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther 13:1515\u20131525. \nhttps:\/\/doi.org\/10.2147\/DDDT.S162913","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"6_CR6","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1056\/NEJMc1810994","volume":"379","author":"JN Buxbaum","year":"2018","unstructured":"Buxbaum JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med 379(21):2086. \nhttps:\/\/doi.org\/10.1056\/NEJMc1810994","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"6_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","volume":"421","author":"SM Johnson","year":"2012","unstructured":"Johnson SM, Connelly S, Fearns C et al (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421(2\u20133):185\u2013203. \nhttps:\/\/doi.org\/10.1016\/j.jmb.2011.12.060","journal-title":"J Mol Biol"},{"issue":"1","key":"6_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"issue":"13","key":"6_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78(13):1371\u20131376. \nhttps:\/\/doi.org\/10.1007\/s40265-018-0968-5","journal-title":"Drugs"},{"issue":"1","key":"6_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18553\/jmcp.2019.25.1.010","volume":"25","author":"K Mickle","year":"2019","unstructured":"Mickle K, Lasser KE, Hoch JS et al (2019) The effectiveness and value of patisiran and inotersen for hereditary transthyretin amyloidosis. J Manag Care Spec Pharm 25(1):10\u201315. \nhttps:\/\/doi.org\/10.18553\/jmcp.2019.25.1.010","journal-title":"J Manag Care Spec Pharm"},{"key":"6_CR11","doi-asserted-by":"publisher","unstructured":"Gales L (2019) Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel) 12(2). \nhttps:\/\/doi.org\/10.3390\/ph12020078","DOI":"10.3390\/ph12020078"},{"issue":"1","key":"6_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams D, Suhr OB, Dyck PJ et al (2017) Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17(1):181. \nhttps:\/\/doi.org\/10.1186\/s12883-017-0948-5","journal-title":"BMC Neurol"},{"key":"6_CR13","doi-asserted-by":"publisher","unstructured":"Al Shaer D, Al Musaimi O, Albericio F et al (2019) 2018 FDA tides harvest. Pharmaceuticals (Basel) 12(2). \nhttps:\/\/doi.org\/10.3390\/ph12020052","DOI":"10.3390\/ph12020052"},{"issue":"10","key":"6_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2174\/0929867013372409","volume":"8","author":"JS Summers","year":"2001","unstructured":"Summers JS, Shaw BR (2001) Boranophosphates as mimics of natural phosphodiesters in DNA. Curr Med Chem 8(10):1147\u20131155","journal-title":"Curr Med Chem"},{"issue":"3","key":"6_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD et al (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23(3):148\u2013157. \nhttps:\/\/doi.org\/10.1080\/13506129.2016.1191458","journal-title":"Amyloid"},{"issue":"5","key":"6_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"MD Benson","year":"2006","unstructured":"Benson MD, Kluve-Beckerman B, Zeldenrust SR et al (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33(5):609\u2013618. \nhttps:\/\/doi.org\/10.1002\/mus.20503","journal-title":"Muscle Nerve"},{"issue":"4","key":"6_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13506129.2017.1374946","volume":"24","author":"MD Benson","year":"2017","unstructured":"Benson MD, Dasgupta NR, Rissing SM et al (2017) Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid 24(4):219\u2013225. \nhttps:\/\/doi.org\/10.1080\/13506129.2017.1374946","journal-title":"Amyloid"},{"issue":"1","key":"6_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"issue":"5","key":"6_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.gt.3301913","volume":"10","author":"QL Lu","year":"2003","unstructured":"Lu QL, Liang HD, Partridge T, Blomley MJ (2003) Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther 10(5):396\u2013405","journal-title":"Gene Ther"},{"issue":"2","key":"6_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/17425255.2013.737320","volume":"9","author":"RZ Yu","year":"2013","unstructured":"Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9(2):169\u2013182. \nhttps:\/\/doi.org\/10.1517\/17425255.2013.737320","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"6_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381\u2013391. \nhttps:\/\/doi.org\/10.1517\/17425250902877680","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"6_CR22","unstructured":"NIH US National Library of Medicine : Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP). \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02175004\n\n. Accessed 11 July 2019"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2199-8-57","volume":"8","author":"AM Adams","year":"2007","unstructured":"Adams AM, Harding PL, Iversen PL et al (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 8:57","journal-title":"BMC Mol Biol"},{"issue":"16","key":"6_CR24","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218. \nhttps:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198\u2013203. \nhttps:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6_CR26","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1021\/acs.nanolett.5b00490","volume":"15","author":"K Ezzat","year":"2015","unstructured":"Ezzat K, Aoki Y, Koo T et al (2015) Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett 15(7):4364\u20134373. \nhttps:\/\/doi.org\/10.1021\/acs.nanolett.5b00490","journal-title":"Nano Lett"},{"issue":"10","key":"6_CR27","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1023\/A:1016260110049","volume":"12","author":"I Walker","year":"1995","unstructured":"Walker I, Irwin WJ, Akhtar S (1995) Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 12(10):1548\u20131553","journal-title":"Pharm Res"},{"key":"6_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. \nhttps:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR29","doi-asserted-by":"crossref","unstructured":"Wen Shen, Cheryl L. De Hoyos, Michael T. Migawa, Timothy A. Vickers, Hong Sun, Audrey Low, Thomas A. Bell, Meghdad Rahdar, Swagatam Mukhopadhyay, Christopher E. Hart, Melanie Bell, Stan Riney, Susan F. Murray, Sarah Greenlee, Rosanne M. Crooke, Xue-hai Liang, Punit P. Seth, Stanley T. Crooke, (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nature Biotechnology 37(6):640\u2013650","DOI":"10.1038\/s41587-019-0106-2"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0771-8_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:04:19Z","timestamp":1598857459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-0771-8_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071607701","9781071607718"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0771-8_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"1 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}